Authors
Affiliations
Andreas Bråve a b, Lindvi Gudmundsdotter a b, Eric Sandström c, B. Kristian Haller d, David Hallengärd a b, Anna-Karin Maltais e, Alan D. King f, Richard R. Stout g, Pontus Blomberg h, Urban Höglund i, Bo Hejdeman c, Gunnel Biberfeld a, Britta Wahren a b
a – Swedish Institute for Infectious Disease Control, Solna, Sweden
b – Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
c- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
d – Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
e – Cyto Pulse Sciences Inc., Solna, Sweden
f – Cellectis Bioresearch, Inc., Glen Burnie MD, USA
g – Bioject Medical Technologies, Tualatin, OR, USA
h – Vecura, Karolinska University Hospital, Huddinge, Sweden
i – Visionar Preclinical AB, Uppsala, Sweden
Peter Glerup, Nanna Grand, Mikala Skydsgaard
Scantox A/S, Lille Skensved, Denmark
V. Golozoubova, T.K. Brodersen, S. Klastrup, M. Oksama, J. Løgsted, A. Makin
Scantox A/S, Lille Skensved, Denmark
A. Makin, Sisse Ellemann-Laursen, Nanna Grand, Gitte Jeppesen, T. Starostka, J. Løgsted, K. Kaaber
Wojciech Senkowski; Xiaonan Zhang; Maria Hägg Olofsson; Ruben Isacson; Urban Höglund; Mats Gustafsson; Peter Nygren; Stig Linder; Rolf Larsson; Mårten Fryknäs
Uppsala University, Klinisk Farmakologi, ing 61 4tr, Dag Hammarskjölds Väg 18, 751 85 Uppsala, Sweden
Michael Karlsson a b 1, Johannes K. Ehinger a b 1, Sarah Piel a b, Fredrik Sjövall a, Johanna Henriksnäs c, Urban Höglund c, Magnus J. Hansson a b, Eskil Elmér a b
a – Mitochondrial Medicine, Department of Clinical Sciences, Lund University, BMC A13, SE-221 84 Lund, Sweden
b – NeuroVive Pharmaceutical AB, Medicon Village, Scheelevägen 2, SE-233 81 Lund, Sweden
c – Scantox Solna (Adlego Biomedical AB), P.O. Box 42, SE-751 03 Uppsala, Sweden
Gustaf Ahlén; Jonas Söderholm; Torunn Tjelle; Rune Kjeken; Lars Frelin; Urban Höglund; Pontus Blomberg; Michael Fons; Iacob Mathiesen; Matti Sällberg
Division of Clinical Microbiology, F68, Karolinska Institutet at Karolinska University Hospital, Huddinge, Stockholm, Sweden
Pham-Tue-Hung Tran1, Naveed Asghar1, Urban Höglund2, Olivia Larsson2, Lars Haag3, Ali Mirazimi4,5, Magnus Johansson1, Wessam Melik1
1 – School of Medical Science, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Örebro University, 703 62 Örebro, Sweden
2 – Scantox Solna (Adlego Biomedical AB), P.O. Box 42, 751 03 Uppsala, Sweden
3 – EM Unit (EMil), Department of Laboratory Medicine, Karolinska Institute, 171 77 Solna, Sweden
4 – Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 141 52 Huddinge, Sweden
5 – National Veterinary Institute, 751 89 Uppsala, Sweden
Madalene Å Andersson1, Lone Bruhn Madsen2, Artur Schmidtchen 3,4,5, Manoj Puthia5
1 – In2Cure AB, Medicon Village, SE-22381 Lund, Sweden.
2 – Scantox Lund (Timeline Bioresearch), Medicon Village, SE-22363 Lund, Sweden.
3 – Copenhagen Wound Healing Center, Bispebjerg Hospital, Department of Biomedical Sciences, University of Copenhagen, DK-2400 Copenhagen, Denmark.
4 – Dermatology, Skåne University Hospital, SE-22185 Lund, Sweden.
5 – Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, SE-22184 Lund, Sweden.
Enamul Haque Mojumdar 1, 2,Lone Bruhn Madsen3,Henri Hansson4,Ida Taavoniku3,Klaus Kristensen3, Christina Persson5,Anna Karin Morén4,Rajmund Mokso6,Artur Schmidtchen7,Tautgirdas Ruzgas1, 2,Johan Engblom1, 2
1 – Department of Biomedical Science, Faculty of Health and Society, Malmö University, SE-205 06 Malmö, Sweden.
2 – Biofilms-Research Center for Biointerfaces (BRCB), Malmö University, SE-205 06 Malmö, Sweden.
3 – Scantox Lund (Timeline Bioresearch AB), Scheelevägen 2, SE-223 63 Lund, Sweden.
4 – Galenica AB, Medeon Science Park, SE-205 12 Malmö, Sweden.
5 – Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
6 – Department of Solid Mechanics & MAX IV Laboratory, Lund University, SE-221 00 Lund, Sweden.
7 – Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden.
8 – Copenhagen Wound Healing Center, Bispebjerg Hospital, Department of Biomedical Sciences, University of Copenhagen, DK-2400 Copenhagen, Denmark.
Sandra Edwards, Nanna Grand
Pham-Tue-Hung Tran1, Urban Höglund2, Olivia Larsson2, Sofia Appelberg3, Ali Murazimi4,5, Magnus Johansson1, Wessam Melin1
1 – School of Medical Science, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Örebro University, 703 62 Örebro, Sweden
2 – Scantox Solna (Adlego Biomedical AB), P.O. Box 42, 751 03 Uppsala, Sweden
3 – Department of Microbiology, Public Health Agency of Sweden, 171 82 Solna, Sweden
4 – Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institution, 141 52 Huddinge, Sweden
5 – National Veterinary Institute, 751 89 Uppsala, Sweden
Rüdiger Groß1, Lívia Mesquita Dias Loiola2,3, Leila Issmail4, Nadja Uhlig4, Valentina Eberlein4, Carina Conzelmann1, Lia‐Raluca Olari1, Lena Rauch1, Jan Lawrenz1, Tatjana Weil1, Janis A. Müller1, Mateus Borba Cardoso3, Andrea Gilg1, Olivia Larsson5, Urban Höglund5, Sandra Axberg Pålsson6, Anna Selch Tvilum2, Kaja Borup Løvschall2, Maria M. Kristensen2, Anna‐Lena Spetz6, Fortune Hontonnou7, Marie Galloux7, Thomas Grunwald4, Alexander N. Zelikin2, Jan Münch1
1 – Institute of Molecular Virology, Ulm University Medical Center, Ulm 89081 Germany
2 – Department of Chemistry and iNano Interdisciplinary Nanoscience Centre, Aarhus University, Aarhus 8000 Denmark
3 – Brazilian Synchrotron Light Laboratory, Brazilian Center for Research in Energy and Materials, Campinas São Paulo, 13083‐970 Brazil
4 – Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig 04103 Germany
5 – Scantox Solna (Adlego Biomedical AB), Solna 171 65 Sweden
6 – Department of Molecular Biosciences, The Wenner‐Gren Institute Stockholm University, Stockholm 10691 Sweden
7 – Université Paris‐Saclay, INRAE, UVSQ, VIM, Jouy‐en‐Josas 78352 France
Sofia Appelberg 1, Gustaf Ahlén2, Jingyi Yan2, Negin Nikouyan2, Sofie Weber3, Olivia Larsson3, Urban Höglund3, Soo Aleman4, Friedemann Weber5, Emma Perlhamre6, Johanna Apro6, Eva‐Karin Gidlund7, Ola Tuvesson7, Simona Salati8, Matteo Cadossi8, Hanna Tegel9, Sophia Hober9, Lars Frelin2, Ali Mirazimi1, and Matti Sällberg2
1 – Public Health Agency of Sweden Solna Sweden
2 – Department of Laboratory Medicine Karolinska Institutet Huddinge Sweden
3 – Scantox Solna (Adlego AB) Uppsala Sweden
4 – Department of Infectious Disease Karolinska University Hospital Huddinge Sweden
5 – Institute for Virology, FB10‐Veterinary Medicine, Justus‐Liebing University Giessen Giessen Germany
6 – Karolinska Trial Alliance Karolinska University Hospital Huddinge Sweden
7 – NorthX Biologics Matfors Sweden
8 – IGEA Bomedical Spa Carpi Italy
9 – Department of Protein Science Royal Institute of Technology Stockholm Sweden
Pham-Tue-Hung Tran1, Naveed Asghar1, Urban Höglund2, Olivia Larsson2, Lars Haag3, Ali Mirazimim4,5, Magnus Johansson1, Wessam Melik1
1 – School of Medical Science, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Örebro University, 703 62 Örebro, Sweden
2 – Scantox Solna (Adlego Biomedical AB), P.O. Box 42, 751 03 Uppsala, Sweden
3 – EM Unit (EMil), Department of Laboratory Medicine, Karolinska Institute, 171 77 Solna, Sweden
4 – Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 141 52 Huddinge, Sweden
5 – National Veterinary Institute, 751 89 Uppsala, Sweden
Wael Bahnan1, Sebastian Wrighton1, Martin Sundwall1, Anna Läckberg1,2, Olivia Larsson3, Urban Höglund3, Hamed Khakzad4,5, Magdalena Godzwon6, Maria Walle6, Elisabeth Elder7, Anna Söderlund Strand8, Lotta Happonen1, Oscar André1, Johannes Kumra Ahnlide1, Thoms Hellmark9, Vidar Wendel-Hansen10, Robert P.A. Wallin11, Johan Malmström1, Lars Malmström1,12, Mats Ohlin6,13, Magnus Rasmussen1,2, Pontus Nordenfelt1
1 – Department of Clinical Sciences Lund, Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden
2 – Infectious Disease Clinic, Skåne University Hospital, Lund, Sweden
3 – Scantox Solna (Adlego Biomedical AB), Uppsala, Sweden
4 – Equipe Signalisation Calcique et Infections Microbiennes, Ecole Normale Supérieure Paris-Saclay, Gif-sur-Yvette, France
5 – Institut National de la Santé et de la Recherche Médicale (INSERM) U1282, Gif-sur-Yvette, France
6 – Department of Immunotechnology, Lund University, Lund, Sweden
7 – Public Health Agency of Sweden, Solna, Sweden
8 – Department of Laboratory Medicine, Clinical Microbiology, Skane University Hospital Lund, Lund University, Lund, Sweden
9 – Department of Clinical Sciences Lund, Nephrology, Skane University Hospital Lund, Lund University, Lund, Sweden
10 – Tanea Medical Ab, Uppsala, Sweden
11 – SciEd Solutions, Stockholm, Sweden
12 – Institute for Computational Science, Zurich, Switzerland
13 – SciLifeLab Drug Discovery and Development, Lund University, Lund, Sweden
Vivi FH Jensen DVM PhD1, Nikolai K Jensen DVM1, Line H Schefe PhD1, Jens Sigh PhD1, Akiyemi Akintomide MSc2, Kari Kaaber DVM3, Sophia G Moesgaard DVM PhD4, Mona H Pedersen PhD1
1 – Global Drug Discovery and Development Sciences, Novo Nordisk A/S, Maaloev, Denmark
2 – Labcorp Early Development Laboratories Limited, Huntingdon, UK
3 – Scantox A/S, Lille Skensved, Denmark
4 – Y-mAbs Therapeutics A/S, Hørsholm, Denmark
Karin M Gilljam PhD, Patrik Stenlund PhD, Simon Standort MSc, Sisse Bindslev Andersen DVM,
Kari Kaaber DVM, Henrik Lund MD PhD, Karl R K Bryn MD
Arman Izadi1, Arsema Hailu1, Magdalena Godwon2, Sebastian Wrighton1, Berit Olofsson1, Tobias Schmidt3,4, Anna Söderlund-Strand5, Elizabeth Elder6, Sofia Appelberg7, Maria Valsjö8, Olivia Larsson8, Vidar Wendel-Hansen9, Mats Ohlin2,10, Wael Bahnan1, Pontus Nordenfelt1,5.
1 – Department of Clinical Sciences Lund, Division of Infection Medicine, Faculty of Medicine, Lund University, 221 84 Lund, Sweden.
2 – Department of Immunotechnology, Faculty of Engineering, Lund University, 221 00 Lund, Sweden.
3 – Department of Clinical Sciences Lund, Division of Pediatrics, Faculty of Medicine, Lund University, 221 84 Lund, Sweden.
4 – Wallenberg Center for Molecular Medicine, Faculty of Medicine, Lund University, 221 84 Lund, Sweden.
5 – Department of Laboratory Medicine, Clinical Microbiology, Skåne University Hospital Lund, Lund University, 221 85 Lund, Sweden.
6 – Department of Microbiology, National Veterinary Institute, 751 89 Uppsala, Sweden.
7 – Department of Microbiology, Public Health Agency of Sweden, 171 82 Stockholm, Sweden.
8 – Scantox A/S, 171 65 Stockholm, Sweden.
9 – Tanea Medical AB, 751 83 Uppsala, Sweden.
10 – SciLifeLab Drug Discovery and Development, Lund University, 221 00 Lund, Sweden.
Torkel Falkenberg, Olivia Larsson, Bengt Hedin, Shigeru Shiraki, Takahisa Karita
Hina Jhelum, Nanna Grand, Kirsten Rosenmay Jacobsen, Sabrina Halecker, Michelle Salerno, Robert Prate, Luise Krüger, Yannick Kristiansen, Ludwig Krabben, Lars Möller, Michael Laue, Benedikt Kaufer, Kari Kaaber, Joachim Denner
Laboratory of Joachim Denner at the Robert Koch Institute and the Institute of Virology was supported by the Deutsche Forschungsgemeinschaft, TRR127.
Paulina Dabrowska-Schlepp1, Andreas Busch1, Jin-Song Shen2, Rachel Y. Cheong3, Lone Bruhn Madsen3,
Daniel Mascher4, Raphael Schiffmann2, Andreas Schlaaf1
1 – Eleva GmbH, Freiburg, Germany
2 – Institute of Metabolic Disease, Baylor, Scott & White Research Institute, Dallas, Texas, USA
3 – Scantox Sweden (Previously Timeline Bioresearch AB), Lund, Sweden
4 – pharm-analyt Labor GmbH, Baden, Austria